AU2022902171A0 - Dosage regimen for the treatment of COPD - Google Patents

Dosage regimen for the treatment of COPD

Info

Publication number
AU2022902171A0
AU2022902171A0 AU2022902171A AU2022902171A AU2022902171A0 AU 2022902171 A0 AU2022902171 A0 AU 2022902171A0 AU 2022902171 A AU2022902171 A AU 2022902171A AU 2022902171 A AU2022902171 A AU 2022902171A AU 2022902171 A0 AU2022902171 A0 AU 2022902171A0
Authority
AU
Australia
Prior art keywords
copd
treatment
dosage regimen
regimen
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022902171A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dimerix Bioscience Pty Ltd
Original Assignee
Dimerix Bioscience Pty Ltd
Filing date
Publication date
Application filed by Dimerix Bioscience Pty Ltd filed Critical Dimerix Bioscience Pty Ltd
Publication of AU2022902171A0 publication Critical patent/AU2022902171A0/en
Priority to PCT/AU2023/050683 priority Critical patent/WO2024026528A1/en
Pending legal-status Critical Current

Links

AU2022902171A 2022-08-02 2022-08-02 Dosage regimen for the treatment of COPD Pending AU2022902171A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/AU2023/050683 WO2024026528A1 (en) 2022-08-02 2023-07-26 Dosage regimen for the treatment of copd

Publications (1)

Publication Number Publication Date
AU2022902171A0 true AU2022902171A0 (en) 2022-08-18

Family

ID=

Similar Documents

Publication Publication Date Title
EP3781564A4 (en) Compounds for the treatment of cancer
EP3952902A4 (en) Dosage forms and regimens for amino acid compounds
EP3908209A4 (en) Filamentary devices for treatment of vascular defects
EP3915583A4 (en) Combined pharmaceutical composition for treating tumor
EP3941462A4 (en) Pharmaceutical compounds for the treatment of complement mediated disorders
EP3862000A4 (en) Medicine for treating chronic cough
EP3939610A4 (en) Combined pharmaceutical composition for treating small cell lung cancer
MX2020010697A (en) Kit, composition and combination therapy for fragile x syndrome.
EP3877418A4 (en) Dosing regimen of anti-tigit antibody for treatment of cancer
EP4010081A4 (en) Combination therapy for treatment of cancer
AU2021397319A9 (en) Combination therapies for the treatment of cancer
EP4041750A4 (en) Dosages for hdac treatment with reduced side effects
AU2022902171A0 (en) Dosage regimen for the treatment of COPD
EP3965789A4 (en) Methods for optimized cannabinoid dosage determination
EP3897602A4 (en) Pharmaceutical combinations for the treatment of cancer
EP4055061A4 (en) Dosage regimen for anti-egfrviii agents
EP3934632A4 (en) Esketamine for the treatment of depression
EP4027984A4 (en) Combination therapy for the treatment of migraines
EP3949990A4 (en) Medicament for treating cancer
EP4010326A4 (en) Kinase inhibitors for the treatment of neurodegenerative diseases
EP3969027A4 (en) Polypeptides for treatment of cancer
EP3941921A4 (en) Therapeutic methods for treating hepatitis b
EP3981473A4 (en) Therapeutic agent for cancer
EP3993801A4 (en) Pharmaceutical composition for treating insomnia
AU2019904858A0 (en) The use of a mutifunctional drug for the treatment of non-alcoholic steatohepatitis